Accupril — Class II drug recall D-0872-2022
Terminated recall by Pfizer Inc., reported 2022-05-25, distributed nationwide. CGMP Deviations: Contains N-nitrosoquinapril above the acceptable limits.
| Recall number | D-0872-2022 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Pfizer Inc., New York, NY, United States |
| Recall initiated | 2022-04-22 |
| Classified | 2022-05-16 |
| Reported by FDA | 2022-05-25 |
| Terminated | 2023-10-05 |
| Distributed | Nationwide (US) |
| Quantity | 2,079 bottles |
| Reason classes | cgmp |
| NDC | 00071-0530-23 |
| Lot numbers | DR9639 |
| Expiration dates | 2023-03-31 |
Product
Accupril (Quinapril HCl Tablets) 10 mg, 90 Tablets Rx only NDC 0071-0530-23 Distributed by: Parke-Davis Division of Pfizer Inc. NY, NY 10017
Reason for recall
CGMP Deviations: Contains N-nitrosoquinapril above the acceptable limits.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0872-2022. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.